Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,312.80
(
0.75%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.66
(
0.01%
)
Bitcoin
73,943.61
(
0.00%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

madrose1

Send PM Follow Ignore
Followers 282
Posts 47139
Boards Moderated 10
Alias Born 04/07/2001

madrose1

Member Level

Re: None

Monday, 10/28/2013 7:40:22 AM

Monday, October 28, 2013 7:40:22 AM

Post# of 257253
Biogen says Q3 revenue gains driven by TECFIDERA
The company says Q3 revenue gains were driven by TECFIDERA with TECFIDERA revenues totaling $286M. AVONEX revenues decreased slightly to $733M, while TYSABRI revenue increased by 46% as a result of Biogen Idec recording 100% of TYSABRI revenues following the company’s acquisition of full rights for the therapy
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now